Digital Transformation of Continuity of Care for Peripherally Inserted Central Catheters: SpadCare Experience
NCT06905119
Administration, Intravenous, Adverse Effects
Pamplona, Navarre, Spain
View Trial DetailsNCT Number: NCT02299466
The purpose of study is to build a Canadian HTPN Registry to collect pertinent demographic and clinical data on the HTPN population in Canada and to determine the factors affecting survival, complications and TPN-dependency. These results will help establish standards of practice and develop future multi-center studies. This will greatly benefit the HTPN patient population.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Foothills Medical Centre, Calgary, Alberta, Canada
The HTPN Registry is website based. Only users inside of Canada will be able to access the website. All data is held in Ontario, Canada and is governed by Ontario and Canadian privacy and security laws. The entry point into the registry will be through a website www.htpnregistry.ca, using a specific HTPN program password for data entry. A code and date of birth will be used to identify each patient. Patient data will be kept confidential and be entered by a member of the TPN team from each participating program. Participating programs will have access to their own database and will be able to compare their patient population to the one of the entire registry. Data entered into the registry will include: 1) Patient demography 2) Nutritional assessment 3) Medications 4) Indications for HTPN 5) Gastrointestinal anatomy following surgeries 6) HTPN regimen 7) Current blood work 8) Vascular access 9) Hospitalizations 10) Survival, 11) Liver complications 12) Metabolic bone disease 13) quality of life. In addition, information regarding each HTPN program will be captured: organization of the TPN team, number of patients under the program, diagnosis and reasons for HTPN, source of funding, geographical coverage, home care utilization, providers. Data will be entered every two years by the one or more HTPN staff monitoring the patients. The data can be entered directly into the website or case report forms can be used to collect the data from the patient charts and facilitate data input into the website.
All patients will be followed prospectively until discontinuation of TPN or death. Descriptive statistics will be performed.
For the entire HTPN population, probability of survival, chronic cholestasis, complicated home parenteral nutrition related liver disease, line infection and metabolic bone disease will be calculated using the Kaplan-Meier method. As of February 2014, 433 patients (85 from UHN) have been entered into the Canadian HTPN registry. The recruitment and data collection is expected to continue for at least 5 more years (until 2019). Participating HTPN programs are: Toronto (Toronto General Hospital, St. Michael's Hospital), Hamilton (Hamilton Health Sciences),Winnipeg (St. Boniface General Hospital), Edmonton (Capital Health/University Of Alberta), Calgary (Foothills Medical Centre), British Columbia (BC Home Parenteral Nutrition Program) and Montreal (McGill University).
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: bi-annually up to 10 years, discontinuation of HTPN or death
Body weight, body mass index
Time frame: baseline
Age, sex, medical history
Time frame: bi-annually up to 10 years, discontinuation of HTPN or death
Immunosuppressors, motility agents, antidiarrheal, sedatives, antidepressors, anticoagulants, insulin, inhibitors of acid secretion, medication to treat liver disease (eg. urso, carnitine, choline…), medication to treat metabolic bone disease (eg. iv/oral calcium, vitamin D, biphosphonate, calcitonin,… are collected from the charts
Time frame: bi-annually up to 10 years, discontinuation of HTPN or death
Short bowel, motility disorder, cancer, surgical complications, pancreatic disorders, other causes of malabsorption
Time frame: bi-annually up to 10 years, discontinuation of HTPN or death
Anatomy as described in medical records
Time frame: bi-annually up to 10 years, discontinuation of HTPN or death
Energy, amino acids, lipids, fluid, electrolytes, vitamins, trace elements
Time frame: bi-annually up to 10 years, discontinuation of HTPN or death
Complete blood count , biochemistry including liver enzymes, total protein, albumin, prealbumin, vit B12, red blood cell folate, iron studies,international normalized ratio /prothrombin time /partial thromboplastin time , cholesterol, triglycerides, trace elements;parathyroid hormone , 24-hr urine oxalate
Time frame: bi-annually up to 10 years, discontinuation of HTPN or death
type of catheter, number of lumens, changes in vascular access, complications (line sepsis, occlusion)
Time frame: bi-annually up to 10 years, discontinuation of HTPN or death
Number/year and TPN related or not TPN related
Time frame: bi-annually up to 10 years, discontinuation of HTPN or death
Alive, death: causes, TPN-related or not TPN-related
Time frame: bi-annually up to 10 years, discontinuation of HTPN or death
Diagnosis, abdominal ultrasound results, liver biopsy results
Time frame: bi-annually up to 10 years, discontinuation of HTPN or death
Bone mineral density results, fracture risk and reported fractures
Time frame: bi-annually up to 10 years, discontinuation of HTPN or death
Karnofsky performance scale (0-100 point scale)
Contact information is provided by the study sponsor or research team.
Johane Allard, MD,FRCPC
CONTACT
Katherine JP Schwenger, BASc, MAN, RD, PhD
CONTACT
University Health Network, Toronto
Other
Home Total Parenteral Nutrition (HTPN) in Canada: A New Website Based Patient Registry
Acronym: HTPN
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06905119
Administration, Intravenous, Adverse Effects
Pamplona, Navarre, Spain
View Trial DetailsNCT07392801
Advanced Glycation and Products, Cardiovascular Diseases
Bordeaux, France
View Trial DetailsNCT07674290
Abnormalities, Multiple, Alstrom Syndrome
Essen, Germany
View Trial DetailsNCT06910943
Avitaminosis, Choline Deficiency
Aurora, Colorado, United States
View Trial Details